PAVAN REDDY to Transplantation Conditioning
This is a "connection" page, showing publications PAVAN REDDY has written about Transplantation Conditioning.
Connection Strength
2.325
-
Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. Blood. 2017 10 12; 130(15):1760-1767.
Score: 0.485
-
Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol. 2014 Jan; 15(1):87-95.
Score: 0.376
-
A phase 2 trial of CD24Fc for prevention of graft-versus-host disease. Blood. 2024 01 04; 143(1):21-31.
Score: 0.189
-
Computational analysis of continuous body temperature provides early discrimination of graft-versus-host disease in mice. Blood Adv. 2019 12 10; 3(23):3977-3981.
Score: 0.143
-
Cognitive Function and Quality of Life in Vorinostat-Treated Patients after Matched Unrelated Donor Myeloablative Conditioning Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 02; 25(2):343-353.
Score: 0.131
-
Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial. Biol Blood Marrow Transplant. 2016 May; 22(5):862-8.
Score: 0.107
-
Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series. Biol Blood Marrow Transplant. 2016 Jan; 22(1):54-60.
Score: 0.105
-
Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission. Ann Hematol. 2015 Jun; 94(6):1033-41.
Score: 0.103
-
Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1407-17.
Score: 0.097
-
Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1426-34.
Score: 0.097
-
Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice. Blood. 2014 May 29; 123(22):3512-23.
Score: 0.096
-
Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)? Curr Stem Cell Res Ther. 2012 May; 7(3):229-39.
Score: 0.084
-
TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes. Biol Blood Marrow Transplant. 2012 Oct; 18(10):1525-32.
Score: 0.084
-
Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood. 2011 Oct 13; 118(15):4258-64.
Score: 0.080
-
Immunization with host-type CD8{alpha}+ dendritic cells reduces experimental acute GVHD in an IL-10-dependent manner. Blood. 2010 Jan 21; 115(3):724-35.
Score: 0.071
-
Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res. 2007 Oct; 150(4):197-214.
Score: 0.060
-
Graft-versus-host disease. Lancet. 2009 May 02; 373(9674):1550-61.
Score: 0.017